TARRYTOWN, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that Ron Lombardi, Chairman, President, & CEO and Christine Sacco, CFO and COO will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, September 10, 2026 at 12:45 p.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
For those unable to participate during the live webcast, a replay option will be available on the Company’s website following the event.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.
This press release was published by a CLEAR® Verified individual.
National survey commissioned by DenTek, the #1 OTC dental guard brand for nighttime teeth grinding, finds nearly 8 in 10 football fans keep thinking about the game after it ends, with many reporting stress-related behaviors that extend into bedtime. NFL legends Ronde & Tiki Barber join DenTek to encourage fans to recognize when football stress may be affecting more than just game day. , /PRNewswire/ -- Football does not always end when the final whistle blows. Findings from the inaugural DenTek Football Stress Test reveal that nearly eight in 10 football fans (78%) continue thinking about football after the game ends, while 77% say they have continued thinking about football after getting into bed. Nearly half have stayed up later than planned because of football, suggesting that for many fans, the game can follow them well into the night. With stress among the most common contributors to nighttime teeth grinding (bruxism), the findings spotlight how football-season stress may have implications that extend beyond game day.
DenTek® Football Stress Test Key Findings
Tiki Barber Trusts DenTek®
Ronde's Barber Nighttime Defense Football Doesn't End at the Final Whistle
Nearly 8 in 10 football fans continue thinking about football after the game ends. 77% have continued thinking about football after getting into bed. 47% have stayed up later than planned because of football. 40% check football scores while in bed. Today's Football Culture Is Amplifying Stress
60% of football fans say football season is stressful. 43% cite social media as a source of football-related stress. 39% say sports betting makes football more stressful. Stress Can Follow Fans to Bed
Among fans who say football season is stressful:
39% report feeling anxious. 32% have trouble falling asleep. 21% experience jaw tension or clenching. 69% say they grind or clench their teeth at least sometimes during stressful football games. Today's football experience extends far beyond kickoff. Between fantasy football, sports betting, around-the-clock injury updates, social media and nonstop group chats, fans have more ways than ever to stay connected to the game. The DenTek Football Stress Test found that only 22% of fans stop thinking about football immediately after a game ends, while nearly half have stayed up later than planned because of football and four in 10 have checked scores from bed. For many fans, the emotional highs and lows don't stop when the game does, with football-related stress extending well into the night. To help bring the Football Stress Test findings to life, DenTek has teamed up with NFL legends and twin brothers Ronde and Tiki Barber, who react to the survey results, weigh in on football's emotional highs and lows, and encourage fans to recognize when football stress extends beyond the game.
"Football has always been emotional, but today's fans never really disconnect from the game," said Ronde Barber. "Between fantasy football, injury updates, social media and nonstop news, football has become part of everyday life for many fans. When the stress of the game follows you beyond the final whistle and into the night, it's worth paying attention—especially if it's affecting your sleep."
"Whether it's your favorite team losing, your fantasy lineup falling apart or a last-second upset, football has a way of sticking with you," added Tiki Barber. " The DenTek Football Stress Test puts real numbers behind what so many fans already experience. If it gets people thinking about how the stress of the game can follow them into the night, that's a conversation worth having."
While football stress may seem like part of being an enthusiastic fan, the Football Stress Test suggests that it can manifest physically as well. Among fans who consider football season stressful, 21% report experiencing jaw tension or clenching, while 69% say they grind or clench their teeth at least sometimes during stressful games. Stress is also one of the most common contributors to nighttime teeth grinding, which many people may not recognize until symptoms such as jaw soreness, morning headaches, tooth sensitivity, or excessive tooth wear begin to appear.
"Football has become a year-round, around-the-clock experience," said Sandra Kasprzak, Director of Marketing at Prestige Consumer Healthcare. "Fans don't simply watch football anymore—they live it. The DenTek Football Stress Test shows that the stress fans experience can extend well beyond the game, including into bedtime. With so many fans also reporting jaw clenching or grinding during stressful games, it's an important reminder that stress can show up in unexpected ways—including in our oral health."
The Football Stress Test is the centerpiece of Fantasy Guards 2.0, DenTek's football-season initiative designed to help fans better understand the connection between football stress, nighttime teeth grinding and oral health. Throughout the season, DenTek and the Barber brothers will continue sharing Football Stress Test findings and reacting to major NFL storylines across earned media and social content.
For consumers who recognize the signs of nighttime teeth grinding, DenTek Nighttime Dental Guards help protect teeth from the effects of nighttime grinding and are available at major retailers nationwide, including Amazon, Walmart, Target, CVS, and Walgreens.
While every football season has its winners and losers, the DenTek Football Stress Test serves as a reminder that when the game follows fans long after the final whistle, it is worth paying attention—not just to the score, but to the signs of stress that may follow fans into the night.
For more information about the Football Stress Test and DenTek Nighttime Dental Guards, visit www.dentek.com and follow @dentek on Instagram.
Survey Methodology: The DenTek Football Stress Test was conducted by OnePoll on behalf of DenTek among 1,000 U.S. adults who identify as football fans. The survey was conducted between July 30 and August 5, 2026.
About DenTek®
DenTek®, from Prestige Consumer Healthcare, is a leading provider of innovative oral care solutions, empowering consumers to take charge of their oral health through proactive prevention. With a range of everyday maintenance, specialized care, and overnight care products, DenTek® coaches people to achieve peak oral health with easy-to-use, performance-driven products.
DenTek®'s portfolio of ready to wear and custom fit mouth guards are BPA-free and protect teeth from nighttime clenching and grinding. With a 6-month guarantee and unmatched comfort, they are the go-to solution for stress-busting oral care. DenTek® nighttime guards are available in three models: Professional Fit, Ultimate, and Comfort-Fit. Learn more at www.dentek.com.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading consumer healthcare company growing trusted, category-defining brands. Headquartered in New York, the Company markets, sells, manufactures and distributes its products across the U.S., Canada, Australia, and select other international markets. Its diverse portfolio of iconic brands includes Breathe Right®, Monistat®, Summer's Eve®, BC®, Goody's®, Dramamine®, Fleet®, Hydralyte®, Gaviscon®, DenTek®, TheraTears®, Clear Eyes®, Compound W®, Dermal Therapy®, Chloraseptic®, Luden's®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, and Debrox®, among others. Learn more at www.prestigeconsumerhealthcare.com.
Disclaimer: The "Fantasy Guards" campaign is not affiliated with, endorsed by, or sponsored by the National Football League (NFL). NFL is a registered trademark of the National Football League.
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH - Free Report) and Stryker (SYK - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Right now, Prestige Consumer Healthcare is sporting a Zacks Rank of #2 (Buy), while Stryker has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that PBH likely has seen a stronger improvement to its earnings outlook than SYK has recently. But this is just one factor that value investors are interested in.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
PBH currently has a forward P/E ratio of 11.24, while SYK has a forward P/E of 21.44. We also note that PBH has a PEG ratio of 1.61. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. SYK currently has a PEG ratio of 2.05.
Another notable valuation metric for PBH is its P/B ratio of 1.27. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, SYK has a P/B of 5.15.
These are just a few of the metrics contributing to PBH's Value grade of A and SYK's Value grade of C.
PBH sticks out from SYK in both our Zacks Rank and Style Scores models, so value investors will likely feel that PBH is the better option right now.
Prestige Brand Holdings is recalling 39,060 bottles of certain Clear Eyes drops over sterility concerns, according to a Food and Drug Administration report.
Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway.
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Premium Brands TSE: PBH said its second-quarter results marked an inflection point as the company began to generate stronger free cash flow from a multiyear capital-spending program designed to expand its manufacturing footprint and U.S. market capacity.
The company reported record sales from continuing operations of C$2.4 billion for the quarter, up C$495 million, or 26.3%, from the second quarter of 2025. Adjusted EBITDA rose 29.5% to C$225 million, while adjusted earnings from continuing operations increased 37.2% to C$79.6 million, or C$1.53 per share.
Get Premium Brands alerts:
Management said the results reflected progress in leveraging capacity created through a capital investment program that began in 2022. The program involved more than C$1.1 billion in project capital expenditures and was intended to transform the company’s production network and strengthen its ability to serve U.S. customers.
U.S. Growth and Specialty Foods Expansion The company said consumer demand for cleaner, healthier and more nutrient-dense food products is creating opportunities in categories including meat sticks, cooked proteins, sandwiches, artisan breads and kettle-cooked meal solutions. Management contrasted that demand with contracting demand for more traditional, highly processed consumer packaged goods.
Specialty Foods’ core U.S. growth initiatives generated organic volume growth of 10.7% during the quarter. Including acquisitions, the group’s U.S. sales increased by C$432.2 million to C$1.2 billion, representing 71.2% of its second-quarter sales, compared with 63.5% a year earlier.
Will Kalutycz, Premium Brands’ CFO, said acquisitions accounted for C$354.5 million of the company’s overall sales increase. Organic volume growth contributed C$74.5 million, while selling-price increases, primarily related to beef-based products, added C$59.9 million.
Within the company’s U.S.-focused operations, the Protein Group recorded 25% organic volume growth, driven by meat snacks and protein products. That performance was partially offset by lower volumes in the Custom Culinary Solutions Group after a customer’s large limited-time sandwich promotion ended in the fourth quarter of 2025. Replacement promotions are not scheduled to begin until early next year, management said.
The company also highlighted its meat-stick business, which grew 83.2% in the second quarter. Premium Brands recently launched its Italia line of shelf-stable, dry-cured meat sticks, produced at its Yorkton, Saskatchewan, facility.
Capital Program Nearing Completion Management said the recently added capacity was built for emerging food categories rather than legacy products. Premium Brands expects to continue onboarding new business and customers over coming quarters, with the additional volume expected to improve free cash flow, margins and returns on invested capital.
The company said it has C$41.6 million remaining to spend on its C$1.1 billion investment plan, which it said will create more than C$2 billion in new sales capacity. During the second quarter, capital expenditures from continuing operations totaled C$59 million, including C$18.3 million tied to the investment plan, C$21.6 million in other project capital expenditures and C$19.1 million in maintenance capital expenditures.
Premium Brands said startup and restructuring costs have declined materially as most capacity expansion projects reach base operating parameters. Kalutycz said the company expects those costs to continue declining in the second half of 2026.
Over the next 12 months, the company expects to close four older facilities while commissioning two new plants, one in the Greater Toronto Area and another in Auburn, Maine. Management said the plant rationalization is expected to create productivity improvements and scale-related efficiencies.
Cash Flow, Debt Reduction and Outlook Premium Brands generated C$68 million in net free cash flow during the second quarter, its first positive quarterly net free cash flow after four years of negative results, according to management. The company expects that trend to accelerate during the second half as it further utilizes new production capacity.
The company’s debt-to-EBITDA ratio declined to 3.8-to-1 from 4.3-to-1 at the end of 2025. Management said both its senior debt and total debt ratios are now within its short-term objectives of 3-to-1 or better for senior debt and 4-to-1 or better for total debt. It expects to reach its longer-term total debt-to-EBITDA target of 3-to-1 or better by early to mid-2027.
Net earnings totaled C$70.9 million, up from C$27.9 million a year earlier. The result included a C$73.9 million gain from the sale of Shaw Bakers and a C$30 million fee received from Clearwater related to certain lobster assets and sales. Those items were partly offset by a C$53.1 million loss related to the shutdown of a value-added beef-processing facility in Ontario and the company’s exit from certain unprofitable sales.
Premium Brands revised its 2026 guidance to sales of C$9.1 billion to C$9.3 billion and adjusted EBITDA of C$840 million to C$870 million. Kalutycz cited delays in product launches, a customer’s decision to shift several large promotions from the second half of 2026 to early 2027, the exit from unprofitable beef-related sales, and weakening consumer demand in certain foodservice segments.
Despite the revised outlook, management said it still expects strong growth in the second half of 2026 and remains on track to meet or exceed its five-year targets of C$10 billion in sales and C$1 billion in EBITDA by the end of 2027.
About Premium Brands (TSE:PBH)Premium Brands Holdings Corp is engaged in specialty food manufacturing, premium food distribution, and wholesale businesses with operations in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nevada, and Washington State. The company's business segments include Specialty Foods, Premium Food Distribution, and Corporate. The Specialty Foods segment consists of its specialty food manufacturing businesses, which contributes about two-thirds of the group revenue; the Premium Food Distribution segment consists of the company's distribution and wholesale businesses; the Corporate segment includes the company's head office activities along with its finance and information systems.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Premium Brands Right Now?Before you consider Premium Brands, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Premium Brands wasn't on the list.
While Premium Brands currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
California State Teachers Retirement System boosted its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 21.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,310 shares of the company’s stock after acquiring an additional 10,117 shares during the quarter. California State Teachers Retirement System owned 0.12% of Prestige Consumer Healthcare worth $3,397,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lido Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 5.4% during the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after buying an additional 192 shares during the period. Cerity Partners LLC lifted its holdings in Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after buying an additional 218 shares during the period. UMB Bank n.a. lifted its holdings in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after acquiring an additional 236 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its position in Prestige Consumer Healthcare by 4.6% during the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after acquiring an additional 256 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets Several research firms recently commented on PBH. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $70.75.
Check Out Our Latest Stock Analysis on PBH
Key Headlines Impacting Prestige Consumer Healthcare Here are the key news stories impacting Prestige Consumer Healthcare this week:
Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment. Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031. Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability. Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions. Prestige Consumer Healthcare Price Performance Prestige Consumer Healthcare stock opened at $54.92 on Friday. Prestige Consumer Healthcare Inc. has a 52 week low of $42.62 and a 52 week high of $71.07. The company’s 50 day moving average price is $48.82 and its two-hundred day moving average price is $56.06. The company has a quick ratio of 2.25, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. The stock has a market cap of $2.60 billion, a P/E ratio of 15.38, a P/E/G ratio of 1.70 and a beta of 0.34.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The company had revenue of $265.71 million during the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the prior year, the business earned $0.90 earnings per share. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.6 earnings per share for the current year.
About Prestige Consumer Healthcare (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Articles Five stocks we like better than Prestige Consumer Healthcare Quantum Earnings Week: Winners and Losers Are Finally Emerging Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia State Teachers Retirement System Has $3.42 Million Holdings in WD-40 Company $WDFC
NEXT HEADLINE »Needham & Company LLC Increases Cloudflare (NYSE:NET) Price Target to $380.00
Prestige Consumer Healthcare NYSE: PBH reported first-quarter fiscal 2027 revenue growth of 6.5%, supported by broad-based category strength, the initial contribution from its Breathe Right acquisition and retailer order timing. The company raised its reported full-year outlook to incorporate Breathe Right and LaCorium Health while maintaining its prior outlook for organic revenue growth.
First-quarter revenue rose to $265.7 million from $249.5 million a year earlier. Organic revenue, excluding foreign exchange effects and the Breathe Right acquisition, increased 3.2%. Adjusted diluted earnings per share increased to $0.98 from $0.95, while adjusted EBITDA rose 5.5%.
Get PBH alerts:
“Our business exceeded sales and earning expectations in the first quarter,” Chairman, President and CEO Ron Lombardi said. “We also delivered record adjusted free cash flow, providing additional flexibility for disciplined capital allocation moving forward.”
Portfolio Strength Offsets Clear Eyes Supply Constraints North America organic revenue increased 4.2%, led by gastrointestinal brands Fleet and Dramamine and dermatological growth driven by Compound W. The company also cited solid growth for TheraTears and Debrox, which helped offset weaker Clear Eyes sales amid continued supply constraints.
Lombardi said Prestige is investing in its Pillar5 sterile ophthalmic manufacturing facility to improve supply consistency and expand long-term capacity for Clear Eyes. The company expects output variability to continue during the first half of fiscal 2027, including the second quarter, before greater stability supports sequential improvement in eye-care shipments during the second half.
Clear Eyes represents less than 3% of sales today, according to Senior Vice President, General Counsel and Corporate Secretary Bill P’Pool. Lombardi described the effort to restore the brand as a multiyear process involving consistent supply, rebuilding safety stocks, restoring the full SKU offering and eventually increasing advertising and marketing support.
International organic revenue declined 2.1% in the quarter, reflecting the timing of distributor orders despite positive consumption trends. Prestige continues to expect the segment to return to its long-term organic growth target of at least 5% for the full year.
Chief Financial Officer and Chief Operating Officer Chris Sacco said e-commerce consumption continued to grow at a double-digit rate. However, some e-commerce order timing benefited the first quarter at the expense of the second quarter. Retailer order timing contributed roughly two percentage points of first-quarter growth, Sacco said.
Acquisitions Add Scale and Lift Outlook Prestige completed the acquisition of the Breathe Right portfolio on June 12 and acquired Australia-based LaCorium Health on July 1. The Breathe Right portfolio contributed $5.9 million of first-quarter revenue.
Breathe Right is expected to generate approximately $200 million in annual revenue, with the flagship nasal strip brand accounting for most of that total. The company said the portfolio has been largely integrated into its operations, systems and warehouse network less than 60 days after the transaction closed.
Lombardi said Prestige sees growth opportunities for Breathe Right through social-media marketing, innovation and international expansion. Recent product introductions include Breathe Right Menthol and Breathe Right Sport, a sweat-resistant strip intended to improve airflow during exercise.
LaCorium is expected to contribute about $40 million in annualized revenue, primarily in Australia. Its Dermal Therapy brand holds positions in therapeutic skincare categories including eczema and cold sore treatments. Prestige said LaCorium employees have joined its Care Pharma office outside Sydney, while broader integration will continue over the rest of the fiscal year.
Management expects additional LaCorium synergies over the next one to two years through sales-force integration, marketing opportunities, distributor optimization and supply-chain efficiencies.
The acquisitions are expected to contribute approximately $190 million in fiscal 2027 revenue. Sacco said Breathe Right remains expected to provide about $0.25 of annualized earnings-per-share accretion in a normal environment, although the initial stub period and timing factors could reduce that contribution by a few cents in the near term.
Margins, Cash Flow and Debt Plans Adjusted gross margin was approximately 55% in the first quarter, flat sequentially but down 120 basis points from the prior year due mainly to higher transportation costs and sales mix. Prestige now expects adjusted gross margin of slightly more than 57% in both the second quarter and full fiscal year, with the increase in outlook attributed entirely to the acquired businesses.
Advertising and marketing spending totaled $34.7 million, or 13% of sales, in the first quarter, reflecting the timing of marketing programs. The company expects advertising and marketing expense to be approximately 14.5% of sales for the full year and second quarter. Adjusted general and administrative expenses are expected to be about 10% of sales for the year, aided by acquisition-related scale.
Adjusted free cash flow reached a quarterly record of $83.7 million, driven largely by working-capital timing. Prestige raised its full-year adjusted free-cash-flow expectation to at least $270 million.
At June 30, net debt was approximately $2 billion. The company funded the Breathe Right acquisition through a new seven-year Term Loan B and cash on hand, with those resources also funding the LaCorium transaction. Prestige also issued $400 million of new unsecured notes to replace notes that were approaching maturity. Its earliest debt maturity is now 2031, and management said it intends to begin paying down prepayable debt during the remainder of fiscal 2027.
Fiscal 2027 Guidance Raised for Acquisitions Prestige raised its fiscal 2027 revenue outlook to a range of $1.290 billion to $1.315 billion. The company maintained its expectation for organic revenue growth of 1% to 3%, saying the higher reported revenue outlook is entirely due to Breathe Right and LaCorium.
Second-quarter revenue is projected at $328 million to $331 million, including both acquisitions. Second-quarter adjusted diluted EPS is expected to be approximately $1.06 to $1.08. Full-year adjusted diluted EPS is forecast at $4.55 to $4.65. Year-end leverage is expected to be just below 4 times. Management expects a modest organic revenue decline in the second quarter because of order timing that benefited the first quarter, while still projecting organic revenue growth for the first half of the fiscal year.
Lombardi said consumer consumption trends remain stable in Prestige’s categories, though shoppers are increasingly focused on value. He cited continued growth in e-commerce and mass retail channels, where consumers can more readily compare prices.
About Prestige Consumer Healthcare (NYSE:PBH)Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.
Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Prestige Consumer Healthcare (PBH - Free Report) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.95 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +10.11%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.39 per share when it actually produced earnings of $1.23, delivering a surprise of -11.51%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Prestige Consumer Healthcare, which belongs to the Zacks Medical - Products industry, posted revenues of $265.71 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 6.18%. This compares to year-ago revenues of $249.53 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Prestige Consumer Healthcare shares have lost about 14.1% since the beginning of the year versus the S&P 500's gain of 12.8%.
What's Next for Prestige Consumer Healthcare?While Prestige Consumer Healthcare has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Prestige Consumer Healthcare was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $276.41 million in revenues for the coming quarter and $4.45 on $1.1 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
VAREX IMAGING (VREX - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 10.
This company is expected to post quarterly earnings of $0.22 per share in its upcoming report, which represents a year-over-year change of +22.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
VAREX IMAGING's revenues are expected to be $216.57 million, up 6.7% from the year-ago quarter.
Q1 Revenue of $265.7 million up 6.5% versus prior yearQ1 Organic sales growth of 3.2%, exceeding expectationsQ1 Diluted EPS of $0.61; Adjusted Diluted EPS of $0.98, up versus prior year $0.95Q1 Cash from Operating Activities $70.8 million; Q1 Adjusted Non-GAAP Free Cash Flow of $83.7 millionClosed the Breathe Right® and LaCorium acquisitions in June and July, respectivelyRaising fiscal 2027 outlook to include acquisitions; anticipate revenue of $1,290 to $1,315 million and Adjusted Diluted EPS outlook to $4.55 to $4.65 TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.
“First quarter performance exceeded our sales and earnings expectations, helped by strength across multiple categories that more than offset a challenging consumer backdrop and Clear Eyes® variability. We were also pleased to close the Breathe Right® acquisition late in the quarter, which added an incremental $6 million in revenue and is positioned well for long-term growth. These strong business results generated robust record adjusted free cash flow in the first quarter, leaving us well positioned to rapidly deleverage in the quarters ahead,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
First Fiscal Quarter Ended June 30, 2026
Reported revenues in the first quarter of fiscal 2027 of $265.7 million increased 6.5% from $249.5 million in the first quarter of fiscal 2026 and increased 3.2% excluding the impacts of foreign currency and a $5.9 million contribution from the acquisition of Breathe Right® and its associated portfolio of brands. The revenue performance versus the prior year comparable period reflected strong organic growth in the Gastrointestinal and Dermatological categories as well as an increase in revenues associated with the acquisition of the Breathe Right® brand and its associated portfolio.
Reported net income for the first quarter of fiscal 2027 totaled $29.2 million, or $0.61 in earnings per diluted share, compared to $47.5 million, or $0.95 in diluted earnings per share, for the comparable period. On an adjusted non-GAAP basis first quarter fiscal 2027 net income totaled $46.5 million, or $0.98 in diluted earnings per share.
Adjustments to net income in the first quarter of fiscal 2027 included certain costs associated with acquisitions including integration, transition, purchase accounting, legal and various other costs, such as costs associated with improving and optimizing the acquired Pillar5 facility for increases in long-term capacity, and associated tax adjustments.
Free Cash Flow and Balance Sheet
The Company's net cash provided by operating activities for the first quarter of fiscal 2027 was $70.8 million, compared to $79.0 million during the prior year comparable period. Non-GAAP adjusted free cash flow in the first quarter of fiscal 2027 of $83.7 million increased compared to $78.2 million in the prior year first quarter. The material increase in free cash flow was attributable to the timing of working capital.
The Company's net debt position as of June 30, 2026 was approximately $2 billion. Subsequent to the quarter, on July 15, 2026 the Company issued $400 million of new 6.25% senior notes due 2034 which replaced the same principal of senior notes previously due in fiscal 2028. The new notes extend the maturity of the amount to July 15, 2034 moving the Company’s closest debt maturity to 2031.
Segment Review
In the fiscal first quarter 2027, the Company established a new product category, Wellness, Sleep & Other, and renamed certain existing product categories to help best incorporate the brands acquired in the Breathe Right® transaction.
North American OTC Healthcare: Segment revenues of $226.2 million for the first quarter fiscal 2027 increased 6.4% compared to the prior year comparable quarter's segment revenues of $212.6 million. The revenue increase was broad-based and included strong organic sales growth in the Gastrointestinal, Dermatological, and Cough, Cold & Allergy categories, as well as an increase in the newly created Wellness, Sleep & Other category from the acquisition of the Breathe Right® brand.
International OTC Healthcare: Fiscal first quarter 2027 segment revenues of $39.5 million increased 6.9% compared to $37.0 million reported in the prior year comparable period. The revenue performance was primarily driven by a $1.4 million contribution from the acquisition of the Breathe Right® brand.
Updated Fiscal 2027 Outlook
Ron Lombardi, Chief Executive Officer, stated, “Our strong initial first quarter performance gives us momentum in both revenue and earnings for full-year fiscal 2027. Our consumption remains healthy for our leading, trusted brands, and we continue to emphasize our proven marketing tactics to succeed in a challenging consumer environment. In addition, our portfolio diversity and business attributes leave us well positioned to manage the continued volatile supply for Clear Eyes®.”
“We are very excited about our recently closed Breathe Right portfolio and LaCorium Health acquisitions in mid-June and July, respectively, and both bring strong long-term growth prospects. Breathe Right® is a category-defining, global brand in the attractive better-breathing space, where we expect to grow the category domestically while expanding the brand's international presence. LaCorium's Dermal Therapy® brand is a leader in therapeutic skin care in Australia, and we anticipate strong sales growth under the Prestige Consumer Healthcare business model, driven by category growth, innovation, and continued geographic expansion."
“We are raising our fiscal 2027 financial outlook for both revenue and EPS, entirely to account for the addition of these two businesses. These acquisitions add nearly 20% to our revenue base and we expect the acquisitions to become increasingly accretive to profitability and cash flow as we move past the near-term and begin to realize business synergies and our brand growth objectives,” Mr. Lombardi concluded.
Initial Fiscal 2027 OutlookCurrent Fiscal 2027 OutlookRevenue$1,100 to $1,121 million$1,290 to $1,315 millionOrganic Revenue Growth+1.0% to +3.0%+1.0% to +3.0%Adjusted Diluted E.P.S.$4.42 to $4.51$4.55 to $4.65Adjusted Free Cash Flow$250 million or more$270 million or more First Quarter Fiscal 2027 Conference Call, Accompanying Slide Presentation and Replay
The Company will host a conference call to review its first quarter fiscal 2027 results today, August 6, 2026 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at http://www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start. The slide presentation can be accessed from the Investor Relations page of the Company’s website by clicking on Webcasts and Presentations.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
Non-GAAP and Other Financial Information
In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section at the end of this earnings release.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "may," "will," "would," “believe,” “momentum,” "expect," “look forward,” "anticipate,” “increasingly,” “positioned,” or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, diluted earnings per share, and adjusted free cash flow; consumption trends; the expected impact of Breathe Right® and LaCorium Health acquisitions on the Company’s revenue and cash flow; and the Company’s ability to manage through the current environment through its business strategy and diverse product portfolio. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of evolving U.S. and international tariffs, labor shortages, inflation and geopolitical instability, consumer trends, the impact of the Company’s advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, as well as Hydralyte® rehydration products and the Dermal Therapy® line of therapeutic skin care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income and Comprehensive Income
(Unaudited) Three Months Ended June 30,(In thousands, except per share data) 2026 2025 Total Revenues $265,710 $249,530 Cost of Sales Cost of sales excluding depreciation 126,466 106,715 Cost of sales depreciation 3,056 2,484 Cost of sales 129,522 109,199 Gross profit 136,188 140,331 Operating Expenses Advertising and marketing 34,668 34,937 General and administrative 43,303 28,456 Depreciation and amortization 5,697 5,182 Total operating expenses 83,668 68,575 Operating income 52,520 71,756 Other expense Interest expense, net 13,945 10,203 Other expense (income), net 34 (224)Total other expense, net 13,979 9,979 Income before income taxes 38,541 61,777 Provision for income taxes 9,364 14,311 Net income $29,177 $47,466 Earnings per share: Basic $0.61 $0.96 Diluted $0.61 $0.95 Weighted average shares outstanding: Basic 47,462 49,475 Diluted 47,604 49,833 Comprehensive income, net of tax: Currency translation adjustments (1,310) 5,404 Total other comprehensive (loss) income (1,310) 5,404 Comprehensive income $27,867 $52,870 Prestige Consumer Healthcare Inc.
Condensed Consolidated Balance Sheets
(Unaudited)(In thousands)June 30, 2026 March 31, 2026 Assets Current assets Cash and cash equivalents$89,127 $63,868Accounts receivable, net of allowance of $19,916 and $18,187, respectively 187,355 191,920Inventories 190,215 159,132Prepaid expenses and other current assets 30,117 16,564Total current assets 496,814 431,484 Property, plant and equipment, net 117,178 121,689Operating lease right-of-use assets 26,040 27,780Finance lease right-of-use assets, net 20,956 21,776Goodwill 650,795 581,109Intangible assets, net 3,243,358 2,299,605Other long-term assets 13,432 10,870Total Assets$4,568,573 $3,494,313 Liabilities and Stockholders' Equity Current liabilities Current portion of long-term debt 10,450 —Accounts payable 36,849 22,791Accrued interest payable 18,015 15,578Operating lease liabilities, current portion 7,010 6,910Finance lease liabilities, current portion 2,699 2,656Other accrued liabilities 78,783 72,989Total current liabilities 153,806 120,924 Long-term debt, net 2,007,235 993,953Deferred income tax liabilities 448,824 447,417Long-term operating lease liabilities, net of current portion 19,129 20,955Long-term finance lease liabilities, net of current portion 17,276 17,968Other long-term liabilities 5,587 5,580Total Liabilities 2,651,857 1,606,797 Total Stockholders' Equity 1,916,716 1,887,516Total Liabilities and Stockholders' Equity$4,568,573 $3,494,313 Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited) Three Months Ended June 30,(In thousands) 2026 2025 Operating Activities Net income$29,177 $47,466 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 8,753 7,666 Loss on disposal of property and equipment 191 — Deferred and other income taxes 193 5,827 Amortization of debt origination costs 465 442 Amortization of acquired inventory step-up 2,840 — Stock-based compensation costs 3,994 3,682 Non-cash operating lease cost 2,090 1,947 Changes in operating assets and liabilities, net of the effects of acquisitions: Accounts receivable 3,450 27,343 Inventories (2,828) (4,441)Prepaid expenses and other current assets 1,557 (10,946)Accounts payable 13,403 2,756 Accrued liabilities 9,831 (813)Operating lease liabilities (2,095) (1,916)Other (233) — Net cash provided by operating activities 70,788 79,013 Investing Activities Purchases of property, plant and equipment (3,703) (838)Acquisitions, net of cash acquired (1,045,000) — Deposits for business acquisitions and other (15,034) (1,100)Net cash (used in) investing activities (1,063,737) (1,938) Financing Activities Proceeds from issuance of Term Loan 1,045,000 — Net (decrease) increase in line of credit 653 — Payments of debt costs (22,476) — Payments of finance leases (576) (608)Proceeds from exercise of stock options — 3,155 Fair value of shares surrendered as payment of tax withholding (2,661) (4,054)Repurchase of common stock — (34,775)Other (1,486) 0 Net cash provided by (used in) financing activities 1,018,454 (36,282)Effects of exchange rate changes on cash and cash equivalents (246) 825 Increase in cash and cash equivalents 25,259 41,618 Cash and cash equivalents - beginning of period 63,868 97,884 Cash and cash equivalents - end of period$89,127 $139,502 Interest paid$11,379 $11,501 Income taxes paid$1,988 $3,253 Prestige Consumer Healthcare Inc.
Condensed Consolidated Statements of Income
Business Segments
(Unaudited) Three Months Ended June 30, 2026(In thousands)North American
OTC Healthcare International
OTC Healthcare ConsolidatedTotal segment revenues*$226,206 $39,504 $265,710Cost of sales 110,265 19,257 129,522Gross profit 115,941 20,247 136,188Advertising and marketing 28,930 5,738 34,668Contribution margin$87,011 $14,509 $101,520Other operating expenses 49,000Operating income $52,520 *Intersegment revenues of $0.7 million were eliminated from the North American OTC Healthcare segment.
Three Months Ended June 30, 2025(In thousands)North American
OTC Healthcare International
OTC Healthcare ConsolidatedTotal segment revenues*$212,578 $36,952 $249,530Cost of sales 92,178 17,021 109,199Gross profit 120,400 19,931 140,331Advertising and marketing 28,954 5,983 34,937Contribution margin$91,446 $13,948 $105,394Other operating expenses 33,638Operating income $71,756 * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment.
About Non-GAAP Financial Measures
In addition to financial results reported in accordance with GAAP, we disclose certain Non-GAAP financial measures ("NGFMs"), including, but not limited to, Non-GAAP Organic Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP Adjusted Gross Margin, Non-GAAP Adjusted Gross Margin Percentage, Non-GAAP Adjusted General and Administrative Expense, Non-GAAP Adjusted General and Administrative Expense Percentage, Non-GAAP EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA, Non-GAAP Adjusted EBITDA Margin, Non-GAAP Adjusted Net Income, Non-GAAP Adjusted Diluted EPS, Non-GAAP Free Cash Flow, Non-GAAP Adjusted Free Cash Flow, and Net Debt. We use these NGFMs internally, along with GAAP information, in evaluating our operating performance and in making financial and operational decisions. We believe that the presentation of these NGFMs provides investors with greater transparency, and provides a more complete understanding of our business than could be obtained absent these disclosures, because the supplemental data relating to our financial condition and results of operations provides additional ways to view our operation when considered with both our GAAP results and the reconciliations below. In addition, we believe that the presentation of each of these NGFMs is useful to investors for period-to-period comparisons of results in assessing shareholder value, and we use these NGFMs internally to evaluate the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.
These NGFMs are not in accordance with GAAP, should not be considered as a measure of profitability or liquidity, and may not be directly comparable to similarly titled NGFMs reported by other companies. These NGFMs have limitations and they should not be considered in isolation from or as an alternative to their most closely related GAAP measures reconciled below. Investors should not rely on any single financial measure when evaluating our business. We recommend investors review the GAAP financial measures included in this earnings release. When viewed in conjunction with our GAAP results and the reconciliations below, we believe these NGFMs provide greater transparency and a more complete understanding of factors affecting our business than GAAP measures alone.
NGFMs Defined
We define our NGFMs presented herein as follows:
Non-GAAP Organic Revenues: GAAP Total Revenues excluding revenues associated with acquisition and the impact of foreign currency exchange rates in the periods presented.Non-GAAP Organic Revenue Change Percentage: Calculated as the change in Non-GAAP Organic Revenues from prior year divided by prior year Non-GAAP Organic Revenues.Non-GAAP Adjusted Gross Margin: GAAP Gross Profit minus amortization of inventory fair value step-up, acquired facility remediation, period overhead and idle capacity costs.Non-GAAP Adjusted Gross Margin Percentage: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues.Non-GAAP Adjusted General and Administrative Expense: GAAP General and Administrative expenses minus costs associated with acquisition.Non-GAAP Adjusted General and Administrative Expense Percentage: Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.Non-GAAP EBITDA: GAAP Net Income before interest expense, net, provision for income taxes, and depreciation and amortization.Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.Non-GAAP Adjusted EBITDA: Non-GAAP EBITDA before amortization of inventory fair value step‑up, acquired facility remediation, period overhead and idle capacity costs and costs associated with acquisitions.Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP adjusted EBITDA divided by GAAP Total Revenues.Non-GAAP Adjusted Net Income: GAAP Net Income before amortization of inventory fair value step-up, depreciation of idle assets during remediation period, acquired facility remediation, period overhead and idle capacity costs, costs associated with acquisitions in General and Administrative Expense, and applicable tax impact associated with these items.Non-GAAP Adjusted Diluted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the diluted weighted average number of shares outstanding during the period.Non-GAAP Free Cash Flow: Calculated as GAAP Net cash provided by operating activities less cash paid for capital expenditures.Non-GAAP Adjusted Free Cash Flow: Non-GAAP free cash flow plus acquisition costs paid.Net Debt: Calculated as total principal amount of debt outstanding ($2,045,000 at June 30, 2026) less cash and cash equivalents ($89,127 at June 30, 2026). Amounts in thousands. The following tables set forth the reconciliations of each of our NGFMs (other than Net Debt, which is reconciled above) to their most directly comparable financial measures presented in accordance with GAAP.
Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related Non-GAAP Organic Revenue Change percentage:
Three Months Ended June 30, 2026 2025(In thousands) GAAP Total Revenues $265,710 $249,530Revenue Change 6.5% Adjustments: Revenues associated with acquisition (a) (5,945) —Impact of foreign currency exchange rates — 2,086Total adjustments (5,945) 2,086Non-GAAP Organic Revenues $259,765 $251,616Non-GAAP Organic Revenue Change 3.2% (a) Revenues of our OTC Wellness Business acquisition are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North America and International OTC Healthcare segments.
Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Non-GAAP Adjusted Gross Margin percentage:
Three Months Ended June 30, 2026 2025 (In thousands) GAAP Total Revenues $265,710 $249,530 GAAP Gross Profit $136,188 $140,331 GAAP Gross Profit as a Percentage of GAAP Total Revenue 51.3% 56.2%Adjustments: Amortization of inventory fair value step‑up 2,840 — Acquired facility remediation, period overhead and idle capacity costs (a) 7,148 — Total adjustments 9,988 — Non-GAAP Adjusted Gross Margin $146,176 $140,331 Non-GAAP Adjusted Gross Margin as a Percentage of GAAP Total Revenues 55.0% 56.2% (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.
Reconciliation of GAAP General and Administrative Expense and related GAAP General and Administrative Expense percentage to Non-GAAP Adjusted General and Administrative expense and related Non-GAAP Adjusted General and Administrative Expense percentage:
Three Months Ended June 30, 2026 2025 (In thousands) GAAP General and Administrative Expense $43,303 $28,456 GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue 16.3% 11.4% Adjustments: Costs associated with acquisition (a) 12,823 — Total adjustments 12,823 — Non-GAAP Adjusted General and Administrative Expense $30,480 $28,456 Non-GAAP Adjusted General and Administrative Expense Percentage as a Percentage of GAAP Total Revenues 11.5% 11.4% (a) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and related Non-GAAP EBITDA Margin, Non-GAAP Adjusted EBITDA and related Non-GAAP Adjusted EBITDA Margin:
Three Months Ended June 30, 2026 2025 (In thousands) GAAP Net Income $29,177 $47,466 Interest expense, net 13,945 10,203 Provision for income taxes 9,364 14,311 Depreciation and amortization 8,753 7,666 Non-GAAP EBITDA $61,239 $79,646 Non-GAAP EBITDA Margin 23.0% 31.9% Adjustments: Amortization of inventory fair value step‑up 2,840 — Acquired facility remediation, period overhead and idle capacity costs (a) 7,148 — Costs associated with acquisitions in G&A (b) 12,823 — Total adjustments 22,811 — Non-GAAP Adjusted EBITDA $84,050 $79,646 Non-GAAP Adjusted EBITDA Margin 31.6% 31.9% (a) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.
(b) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.
Reconciliation of GAAP Net Income and GAAP Diluted Earnings Per Share to Non-GAAP Adjusted Net Income and related Non-GAAP Adjusted Diluted Earnings Per Share: Three Months Ended June 30, 2026 2026
Diluted
EPS 20252025
Diluted
EPS(In thousands, except per share data) GAAP Net Income and Diluted EPS $29,177 $0.61 $47,466$0.95Adjustments: Amortization of inventory fair value step‑up 2,840 0.06 — —Depreciation of idle assets during remediation period (a) 70 — — —Acquired facility remediation, period overhead and idle capacity costs (b) 7,148 0.15 — —Costs associated with acquisition in General and Administrative Expense (c) 12,823 0.27 — —Tax impact of adjustments (d) (5,559) (0.12) — —Total adjustments 17,322 0.36 — —Non-GAAP Adjusted Net Income and Adjusted Diluted EPS $46,499 $0.98 $47,466$0.95 (a) Represents depreciation expense recorded during the remediation period following the acquisition of Pillar5, during which certain production lines were not operating. Management believes this depreciation is not reflective of expected ongoing depreciation levels once the facility is fully remediated and operating at normal production levels.
(b) Represents manufacturing and administrative overhead incurred during a remediation period following the acquisition of Pillar5, during which production was significantly constrained. As a result, normal overhead absorption levels were not achieved, leading to elevated unit costs. Management believes these costs are not indicative of the Company’s expected ongoing operating cost structure once the facility is fully remediated and operating at normal production levels.
(c) Costs related to the consummation of the acquisition process such as legal and other acquisition-related professional fees.
(d) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of specific Non-GAAP performance measure.
Note: Amounts may not add due to rounding.
Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow: Three Months Ended June 30, 2026 2025 (In thousands) GAAP Net Income $29,177 $47,466 Adjustments: Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows 18,526 19,564 Changes in operating assets and liabilities, net of effects of acquisitions as shown in the Statement of Cash Flows 23,085 11,983 Total adjustments 41,611 31,547 GAAP Net cash provided by operating activities 70,788 79,013 Purchases of property and equipment (3,703) (838)Non-GAAP Free Cash Flow 67,085 78,175 Acquisition and other costs paid 16,664 — Non-GAAP Adjusted Free Cash Flow $83,749 $78,175 Outlook for Fiscal Year 2027:
Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Free Cash Flow
and Projected Non-GAAP Adjusted Free Cash Flow:(In millions) Projected FY'27 GAAP Net cash provided by operating activities$277 Additions to property and equipment for cash (26)Projected FY'27 Non-GAAP Free Cash Flow 251 Acquisition and other costs paid 19 Projected FY'27 Non-GAAP Adjusted Free Cash Flow$270 Reconciliation of Projected GAAP Diluted EPS to Projected Non-GAAP Adjusted Diluted EPS (a):
Low HighProjected FY'27 GAAP Diluted EPS$4.18 $4.28Adjustments: Costs associated with Pillar5 manufacturing optimization and integration 0.13 0.13Costs associated with acquisitions of the Breathe Right portfolio and LaCorium Health 0.24 0.24Projected FY'27 Non-GAAP Adjusted Diluted EPS$4.55 $4.65 (a) The above reconciliation of this forward-looking non-GAAP financial measure only includes adjustments for Q1 2027 and does not include additional adjustments for the remainder of fiscal 2027. These future adjustments are highly uncertain, given the significant variability and difficulty in making accurate projections of the adjustments related to the Breathe Right portfolio and LaCorium Health acquisitions and the costs associated with Pillar5 manufacturing optimization and integration. As a result, the Company is unable to quantify those future adjustments, which are likely significant, without unreasonable efforts.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819 [email protected]
Bank of New York Mellon Corp cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 4.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 311,341 shares of the company’s stock after selling 13,557 shares during the quarter. Bank of New York Mellon Corp owned 0.66% of Prestige Consumer Healthcare worth $18,453,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of PBH. UMB Bank n.a. raised its stake in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd purchased a new position in Prestige Consumer Healthcare during the 4th quarter valued at about $29,000. Geneos Wealth Management Inc. raised its position in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Torren Management LLC purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $35,000. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.
Prestige Consumer Healthcare Stock Performance NYSE:PBH opened at $52.17 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The firm has a market cap of $2.47 billion, a PE ratio of 13.34, a P/E/G ratio of 1.66 and a beta of 0.35. The firm has a 50 day simple moving average of $48.22 and a 200-day simple moving average of $56.62. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $75.63.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s revenue was down 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.
Insider Buying and Selling at Prestige Consumer Healthcare In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets Several research analysts recently issued reports on the company. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group lowered their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $70.75.
Check Out Our Latest Stock Report on PBH
About Prestige Consumer Healthcare (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
See Also Five stocks we like better than Prestige Consumer Healthcare Why SK hynix Could Be the Best AI Chip Stock to Buy Now Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Why Bloom Energy May Be the Most Important AI Infrastructure Stock Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Lowers Stake in United Natural Foods, Inc. $UNFI
NEXT HEADLINE »Stephens Issues Positive Forecast for Cheesecake Factory (NASDAQ:CAKE) Stock Price
Dimensional Fund Advisors LP increased its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 3.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,672,777 shares of the company’s stock after purchasing an additional 91,710 shares during the quarter. Dimensional Fund Advisors LP owned 5.65% of Prestige Consumer Healthcare worth $158,414,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also made changes to their positions in PBH. Massachusetts Financial Services Co. MA increased its holdings in Prestige Consumer Healthcare by 10.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after purchasing an additional 60,496 shares in the last quarter. Leeward Investments LLC MA raised its holdings in shares of Prestige Consumer Healthcare by 23.3% in the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after purchasing an additional 73,162 shares during the period. Legato Capital Management LLC raised its stake in Prestige Consumer Healthcare by 532.4% in the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock valued at $1,713,000 after acquiring an additional 23,382 shares during the period. Brandes Investment Partners LP boosted its holdings in shares of Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after acquiring an additional 292,744 shares during the period. Finally, Bessemer Group Inc. boosted its stake in Prestige Consumer Healthcare by 20.9% in the 1st quarter. Bessemer Group Inc. now owns 374,691 shares of the company’s stock valued at $22,207,000 after purchasing an additional 64,760 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity In other news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.50% of the company’s stock.
Prestige Consumer Healthcare Stock Up 0.0% Shares of NYSE PBH opened at $49.67 on Monday. The company has a 50 day simple moving average of $47.94 and a 200 day simple moving average of $56.87. The firm has a market cap of $2.35 billion, a PE ratio of 12.70, a price-to-earnings-growth ratio of 1.60 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $77.03. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.
Wall Street Analysts Forecast Growth A number of research analysts have issued reports on PBH shares. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $70.75.
Get Our Latest Analysis on Prestige Consumer Healthcare
About Prestige Consumer Healthcare (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories Five stocks we like better than Prestige Consumer Healthcare RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEArmstrong World Industries, Inc. $AWI Stock Holdings Decreased by Dimensional Fund Advisors LP
NEXT HEADLINE »Ardmore Road Asset Management LP Has $33.94 Million Holdings in Spotify Technology $SPOT
Fifth Third Bancorp boosted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 8,130.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,052 shares of the company’s stock after buying an additional 28,699 shares during the quarter. Fifth Third Bancorp owned approximately 0.06% of Prestige Consumer Healthcare worth $1,722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently made changes to their positions in the company. Norges Bank bought a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $36,954,000. Brandes Investment Partners LP raised its position in shares of Prestige Consumer Healthcare by 93.2% in the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after purchasing an additional 292,744 shares during the period. Capital Research Global Investors raised its position in shares of Prestige Consumer Healthcare by 107.9% in the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock valued at $34,639,000 after purchasing an additional 291,425 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Prestige Consumer Healthcare by 316.1% during the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after buying an additional 229,311 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Prestige Consumer Healthcare by 28.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after buying an additional 120,965 shares during the period. 99.95% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Prestige Consumer Healthcare In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by insiders.
Prestige Consumer Healthcare Stock Performance NYSE PBH opened at $48.91 on Thursday. The company’s 50 day simple moving average is $47.82 and its two-hundred day simple moving average is $57.04. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $77.45. The stock has a market capitalization of $2.32 billion, a PE ratio of 12.51, a P/E/G ratio of 1.58 and a beta of 0.35.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million for the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter last year, the firm earned $1.32 earnings per share. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.
Analyst Ratings Changes PBH has been the subject of a number of recent research reports. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $70.75.
Read Our Latest Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Company Profile (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories Five stocks we like better than Prestige Consumer Healthcare Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding PBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report).
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of New York Mellon Corp Sells 631,362 Shares of BioMarin Pharmaceutical Inc. $BMRN
NEXT HEADLINE »Fifth Third Bancorp Raises Position in Reynolds Consumer Products Inc. $REYN
Bessemer Group Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) by 20.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 374,691 shares of the company’s stock after buying an additional 64,760 shares during the period. Bessemer Group Inc. owned about 0.79% of Prestige Consumer Healthcare worth $22,207,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in PBH. Lido Advisors LLC increased its holdings in shares of Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock worth $235,000 after acquiring an additional 192 shares during the last quarter. Cerity Partners LLC boosted its position in Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after purchasing an additional 218 shares during the period. UMB Bank n.a. boosted its position in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in shares of Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its holdings in shares of Prestige Consumer Healthcare by 4.6% in the third quarter. Diversify Advisory Services LLC now owns 5,837 shares of the company’s stock valued at $354,000 after purchasing an additional 256 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.
Prestige Consumer Healthcare Stock Performance Shares of NYSE PBH opened at $49.92 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The firm has a market cap of $2.36 billion, a price-to-earnings ratio of 12.77, a P/E/G ratio of 1.60 and a beta of 0.35. The stock’s fifty day moving average price is $47.91 and its two-hundred day moving average price is $57.35. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $77.45.
Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s quarterly revenue was down 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.
Wall Street Analyst Weigh In A number of analysts have recently issued reports on the stock. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $70.75.
Get Our Latest Report on Prestige Consumer Healthcare
Insiders Place Their Bets In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by company insiders.
Prestige Consumer Healthcare Company Profile (Free Report)
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Featured Stories Five stocks we like better than Prestige Consumer Healthcare Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEProcter & Gamble Company (The) $PG Shares Bought by AIA Group Ltd
NEXT HEADLINE »Bessemer Group Inc. Grows Stock Holdings in Infosys Ltd. $INFY
On June 30, 2026, John Rogers (Trades, Portfolio) executed a notable transaction involving Prestige Consumer Healthcare Inc (PBH). The transaction saw an additi
Investors in Prestige Consumer Healthcare Inc. (PBH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $45 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Prestige Consumer Healthcare shares, but what is the fundamental picture for the company? Currently, Prestige Consumer Healthcare is a Zacks Rank #5 (Strong Sell) in the Medical – Products industry that ranks in the Bottom 31% of our Zacks Industry Rank. Over the last 60 days, no analyst increased the earnings estimates for the current quarter, while two have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.05 per share to 89 cents in that period.
Given the way analysts feel about Prestige Consumer Healthcare right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health (“LaCorium”), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026.
Completion of LaCorium Health Acquisition
The Company completed the acquisition on July 1, 2026. The closing was finalized pursuant to the terms of the definitive agreement announced on May 13, 2026, under which Prestige agreed to acquire LaCorium for approximately $150 million in cash. The Company financed the transaction with cash on hand and existing credit facilities.
Founded in Australia and introduced in 1998, LaCorium is a leader in Australian therapeutic skin care designed to treat individual skin ailments. Products are sold under the Dermal Therapy®, Flexitol®, and Crampeze® brands in need-state categories such as lip care (cold sores), skin care (eczema & acne), foot care (heel balm, antifungal), hair & scalp (eczema), and more. Approximately 75% of LaCorium’s sales are generated in Australia, where the brand holds the #1 market position in lip care and the #3 position in foot care.
LaCorium generates approximately $40 million in revenue annually and is expected to generate approximately $12 million in EBITDA, including the benefits from anticipated synergies, once the business is fully integrated. The Company expects LaCorium to deliver strong long-term revenue growth, supported by category growth, innovation, and continued geographic expansion.
Pricing of Senior Notes Offering
Prestige has also priced an offering of $400 million in aggregate principal amount of 6.25% senior notes due 2034 (the “notes”) in a private offering. The sale of the notes is expected to be completed on or about July 15, 2026, subject to customary closing conditions. The notes will be senior unsecured obligations of Prestige Brands, Inc. and will be guaranteed by the Company and certain of its domestic subsidiaries. The Company intends to use the net proceeds from the offering, together with cash on hand, to redeem all $400 million of Prestige’s’ outstanding 5.125% Senior Notes due January 2028, and to pay related fees and expenses. The change in interest expense is contemplated in Prestige’s medium-term outlook provided on May 13, 2026.
The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
First Quarter Fiscal 2027 Earnings Call
The Company will issue its fiscal 2027 first quarter earnings release on Thursday, August 6, 2026 before the market open. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.
To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.
A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company’s Investor Relations page.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “expected,” “will,” and “intends” (or the negative or other derivatives of each of these terms) or similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the completion of the sale of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including general economic and business conditions. A discussion of other factors that could cause results to vary is included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
Investor Relations Contact
Phil Terpolilli, CFA, 914-524-6819 [email protected]
When Alphabet joined the Dow Jones Industrial Average (^DJI +1.14%), the financial press couldn't stop talking about it. And when Warren Buffett's Berkshire Hathaway made it a top portfolio holding, that drumbeat got louder.
There's nothing wrong with owning Alphabet -- it's a great business. But the investors who've built real wealth over decades aren't always the ones chasing the loudest names. Sometimes it's the quiet compounders that win.
Prestige Consumer Healthcare (PBH +2.62%) is not a name you'll hear on CNBC. The company sells over-the-counter healthcare products like Monistat, Dramamine, Clear Eyes, Chloraseptic, and BC Powder. These brands live in medicine cabinets and bathroom drawers across North America. It's boring in the best possible way.
But something big just happened. On June 15, Prestige closed its largest acquisition in company history: the $1.045 billion purchase of the Breathe Right brand and several other OTC labels from Foundation Consumer Healthcare. Breathe Right -- the nasal strip that's been on athletes' faces and on nightstands next to CPAP machines for decades -- just became Prestige's single largest brand.
Today's Change
(
2.62
%) $
1.26
Current Price
$
49.42
The Breathe Right play The deal brings in roughly $200 million in annual revenue and $95 million in earnings before interest, taxes, depreciation, and amortization (EBITDA). It also includes Dimetapp, long the go-to children's cough and cold brand, and Anbesol for oral pain relief. But Breathe Right is the anchor.
What Prestige sees in that brand goes beyond the strip itself. Breathe Right has a foothold in sleep wellness, athletic performance, allergy relief, and congestion.
CEO Ron Lombardi pointed to the company's work with Dramamine as the blueprint. Prestige acquired Dramamine when it was thought of as strictly a motion sickness brand and then expanded it into a broader remedy for everyday nausea and vertigo. The Breathe Right playbook will likely look similar: invest in consumer awareness, broaden the use cases, and build the category.
That model has worked before. Historically, about 64% of Prestige's revenues come from brands that hold the No. 1 position in their categories. The company has spent years assembling a portfolio of what it calls "category synonymous" brands -- names so embedded in consumer memory that the brand name effectively is the category.
Image source: Getty Images.
A quieter GLP-1 angle One thing that doesn't get enough attention is that Prestige has been threading its portfolio into the GLP-1 conversation. As millions of Americans start using weight-loss medications like Ozempic and Wegovy, they're dealing with side effects that Prestige's brands are built for: nausea, digestive issues, and constipation.
The company has been marketing Dramamine and Fleet toward GLP-1 users seeking relief. That's a smart repositioning of existing assets. And it costs next to nothing compared to launching a new product.
Going international The Breathe Right deal isn't the only move this year. Prestige also announced an agreement to acquire LaCorium Health, a leading therapeutic skincare brand in Australia. The company already operates in Australia through its Hydralyte and Fess brands, so this deepens an existing footprint rather than planting a flag in unfamiliar territory.
International OTC healthcare represents a real runway. The markets are fragmented, consumer trust in established brands matters, and Prestige's asset-light model travels well.
The risk worth naming None of this comes free. The Breathe Right deal pushed Prestige's net leverage to roughly 4.0x EBITDA at closing. That's a real debt load, and the company needs its free cash flow to behave.
Management has projected a return below 3.0x leverage by fiscal 2028 -- but that assumes execution holds. Integration stumbles, a softening consumer, or a brand that doesn't respond to investment are all real possibilities here.
Prestige Consumer Healthcare isn't going to light up your portfolio overnight. What it offers is a business with category-leading brands, a repeatable acquisition model, and a fresh runway through Breathe Right. For investors willing to look past the big tech headlines, this OTC brand machine is worth a close look.
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Brands”), intends to offer, subject to market and other conditions, up to $400 million in aggregate principal amount of new senior notes due 2034 (the “notes”) in a private offering. The notes will be senior unsecured obligations of Prestige Brands and will be guaranteed by the Company and certain of its domestic subsidiaries.
The Company intends to use the net proceeds from the proposed offering, together with cash on hand, to redeem all $400 million of Prestige Brands’ outstanding 5.125% Senior Notes due 2028 (the “2028 notes”), and to pay related fees and expenses.
Prestige Brands expects to give notice of its intention to redeem the 2028 notes pursuant to the indenture governing the 2028 notes, at a redemption price equal to 100.0% of the principal amount thereof, plus accrued and unpaid interest to the date of redemption. The redemption of the 2028 notes is conditioned on the completion of an offering of new unsecured senior notes in an aggregate principal amount of at least $400 million (the “Financing Condition”). Prestige Brands may waive the Financing Condition in its sole discretion.
The notes and related guarantees are being offered only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) or, outside the United States, to persons other than “U.S. persons” in compliance with Regulation S under the Securities Act. This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes and related guarantees. Any offers of the notes and related guarantees will be made only by means of a private offering memorandum. The notes and related guarantees have not been registered under the Securities Act, or the securities laws of any other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat ® and Summer’s Eve ® women’s health products, BC ® and Goody’s ® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden’s ® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste ® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.
Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” generally can be identified by the use of forward-looking terminology such as “intends,” “expects,” “may,” and “will” (or the negative or other derivatives of each of these terms) or similar terminology. The “forward-looking statements” include, without limitation, statements regarding the Company’s expectations regarding the offering of the notes and the redemption of the 2028 notes. These statements are based on management’s estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expected as a result of a variety of factors, including general economic and business conditions. A discussion of other factors that could cause results to vary is included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and other periodic reports filed with the Securities and Exchange Commission.
, /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company's disappointing Q4 2026 financial results.
The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
The firm encourages Prestige investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/pbh
Contact the Firm Now: [email protected]
844-916-0895
Prestige Consumer Healthcare Inc. (PBH) Investigation:
Prestige develops, manufactures, markets, sells, and distributes OTC health and personal care products to a wide range of customers. Clear Eyes®, a line of eye drops that provide cooling comfort and multi-symptom relief from redness, dryness, and itchiness is one of the company's major brands.
The investigation is focused on the propriety of Prestige's pre-May 14 disclosures concerning the performance of its recently acquired Pillar5 facility which the company touted as resolving persistent Clear Eyes® supply chain constraints and returning the brand to its leading market share position.
Investors' expectations were dashed on May 13, 2026. That day, Prestige reported that its Q4 2026 revenues came in 5% lower than the year earlier quarter and 6.4% lower than the previous quarter.
More concerning, as compared to Q4 2025, North America OTC Eye & Ear Care, the segment which Clear Eyes® falls within, reported a whopping 20.6% decrease in revenues while its International OTC reported an equally disturbing year-over-year 31.3% decrease. Similarly, these business' revenues were massively lower on a sequential basis.
During the company's earnings call the next day, management revealed that there were "Clear Eyes supply constraints" and said "as we've seen in the past of dealing with the previous owners and management at Pillar5, is what would start out as an expected one-week shutdown to do something turned into two weeks, would turn into three, which would turn into four as things either got more complex or the work got expanded[.]"
In response, the market quickly reacted, sending the price of Prestige shares significantly lower.
"Our investigation is focused on when Prestige and its management first became aware that the Pillar5 facility was not performing and whether they might have misled investors about progress in remediating Clear Eyes® supply issues," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.
If you invested in Prestige and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »
If you'd like more information and answers to other frequently asked questions about the firm's Prestige investigation, read more »
Whistleblowers: Persons with non-public information regarding Prestige should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SAN FRANCISCO, June 23, 2026 (GLOBE NEWSWIRE) -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant revenue declines and production problems driving the company’s disappointing Q4 2026 financial results.
The surprise developments have prompted national shareholder rights firm Hagens Berman to open an investigation into whether, before May 14, Prestige was sufficiently transparent regarding its ability to remediate supply chain constraints and, if not, whether the company violated the federal securities laws.
The firm encourages Prestige investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/pbh
Contact the Firm Now: [email protected]
844-916-0895
Prestige Consumer Healthcare Inc. (PBH) Investigation:
Prestige develops, manufactures, markets, sells, and distributes OTC health and personal care products to a wide range of customers. Clear Eyes®, a line of eye drops that provide cooling comfort and multi-symptom relief from redness, dryness, and itchiness is one of the company’s major brands.
The investigation is focused on the propriety of Prestige’s pre-May 14 disclosures concerning the performance of its recently acquired Pillar5 facility which the company touted as resolving persistent Clear Eyes® supply chain constraints and returning the brand to its leading market share position.
Investors’ expectations were dashed on May 13, 2026. That day, Prestige reported that its Q4 2026 revenues came in 5% lower than the year earlier quarter and 6.4% lower than the previous quarter.
More concerning, as compared to Q4 2025, North America OTC Eye & Ear Care, the segment which Clear Eyes® falls within, reported a whopping 20.6% decrease in revenues while its International OTC reported an equally disturbing year-over-year 31.3% decrease. Similarly, these business’ revenues were massively lower on a sequential basis.
During the company’s earnings call the next day, management revealed that there were “Clear Eyes supply constraints” and said “as we’ve seen in the past of dealing with the previous owners and management at Pillar5, is what would start out as an expected one-week shutdown to do something turned into two weeks, would turn into three, which would turn into four as things either got more complex or the work got expanded[.]”
In response, the market quickly reacted, sending the price of Prestige shares significantly lower.
“Our investigation is focused on when Prestige and its management first became aware that the Pillar5 facility was not performing and whether they might have misled investors about progress in remediating Clear Eyes® supply issues,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Prestige and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to other frequently asked questions about the firm’s Prestige investigation, read more »
Whistleblowers: Persons with non-public information regarding Prestige should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Right® brand and certain other brands.
The closing was finalized pursuant to the terms of the asset purchase agreement, announced on March 20, 2026, under which Prestige agreed to acquire the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits valued at $150 million. Breathe Right®, created in the 1990s, is an iconic #1 brand synonymous with the nasal strip category. It will become the company’s largest brand and represents expansion into a new category for Prestige.
The Company financed the transaction with a combination of available cash on hand and a completed financing of a new Term Loan B.
Further details regarding the transaction and benefits of Prestige are detailed in a presentation dated March 20, 2026 available on the Company’s website at https://ir.prestigebrands.com/.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips, Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PRESTIGE CONSUMER HEALTHCARE (PBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 13, 2026, Prestige Consumer annou.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PRESTIGE CONSUMER HEALTHCARE (PBH), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year."
In the associated earnings call, the Company’s CEO Ron Lombardi revealed "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.
Contact Us To Participate or Learn More:
If you purchased Prestige Consumer securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith continues its investigation on behalf of Prestige Consumer Healthcare (âPrestige Consumerâ or the âCompanyâ) (NYSE: [url=
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Prestige Consumer Healthcare (“Prestige Consumer” or the “Company”) (NYSE: PBH) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON PRESTIGE CONSUMER HEALTHCARE (PBH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On May 13, 2026, Prestige Consumer announced fourth quarter and full year 2026 earnings, including that, "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year."
In the associated earnings call, the Company’s CEO Ron Lombardi revealed "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, shares of Prestige Consumer fell $5.88 per share, or 11.35%, to close at $45.93 on May 14, 2026.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Prestige Consumer should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LOS ANGELES, May 24, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or “the Company”) (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335 [email protected]
www.schallfirm.com
New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) ("Prestige Consumer Healthcare Inc.") concerning potential violations of the federal securities laws.
During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4. Management further projected projected free cash flow of $245 million or more for the full year alongside an adjusted EPS of $4.54. When Q4 results were reported, adjusted gross margin came in at approximately 55.4%, full-year free cash flow totaled $228 million, and adjusted diluted EPS was only 4.38; all three missed Prestige's internal projections.
Separately, Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium during the period. The acquisition was not discussed on the Q3 earnings call and was absent from the forward guidance framework presented to investors. PBH shares declined sharply following the Q4 disclosure.
If you suffered a loss on your Prestige Consumer Healthcare Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212)363-7500
Fax: (212)363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298721
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Investors in Prestige Consumer Healthcare Inc. (PBH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 16, 2026 $45 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Prestige Consumer shares, but what is the fundamental picture for the company? Currently, Prestige Consumer is a Zacks Rank #4 (Sell) in the Medical – Products industry that ranks in the Bottom 33% of our Zacks Industry Rank. Over the last 60 days, no analyst increased their earnings estimates for the current quarter, while one has dropped the estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.05 per share to 96 cents in that period.
Given the way analysts feel about Prestige Consumer right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference virtually on Monday, June 8, 2026 at 9:45 a.m. ET. A live webcast of this event will be available at www.prestigeconsumerhealthcare.com under the "Investors” section and the "Events and Presentations" tab, or by using the following link:
For those unable to participate during the live webcast, a replay option will be available on the Company’s website following the event.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare markets, sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia, and in certain other international markets. The Company’s diverse portfolio of brands include Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. (“Prestige” or the “Company”) (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that “for fiscal ‘26, revenues decreased 4.5% organically versus the prior year” and “[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year.” In the associated earnings call, the Company’s CEO Ron Lombardi revealed that “in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates.”
On this news, Prestige’s stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Amylyx Stock: Why the Full Pipeline Story MattersAmylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Klee described avexitide as a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, or PBH, a condition he said affects about 160,000 people in the U.S. He said the company expects that population to grow over time.
Get Amylyx Pharmaceuticals alerts:
3 small-cap biotechs with potential breakthroughs in 2024PBH is characterized by persistent, symptomatic severe hypoglycemia, Klee said, including neuroglycopenia, in which the brain does not receive enough glucose. He said patients can experience severe confusion, loss of consciousness and seizures, and that there are currently no approved treatments for the condition.
Klee said PBH is driven by elevated GLP-1 response after bariatric surgery, with some patients producing 10 to 20 times normal GLP-1 levels. That can cause insulin spikes and severe hypoglycemia. Avexitide is designed to block the GLP-1 receptor and reduce downstream hypoglycemia.
Phase 3 Readout Expected in Third Quarter These biotechs targeting multiple neurodegenerative diseasesKlee said Amylyx expects topline results from its Phase 3 pivotal trial of avexitide in the third quarter. The company completed enrollment at the end of March, and the study includes a 16-week double-blind, placebo-controlled period, followed by time for database cleaning, lock and analysis.
The Phase 3 trial is testing a 90 mg dose of avexitide. Klee said an earlier 60 mg dose showed effectiveness, but investigators observed possible breakthrough hypoglycemic events late at night or early in the morning. Pharmacokinetic analysis suggested coverage could be improved, leading to the higher dose.
He said the 90 mg dose provided coverage across the full day and night cycle in a Phase 2b trial, where the company observed reductions in both daytime and nighttime hypoglycemia as measured by continuous glucose monitoring, along with what he described as a good safety profile.
Klee said the Phase 3 trial was designed to be consistent with earlier studies, including the requirement that participants have frequent hypoglycemic events during a run-in period. He said the study is 90% powered to detect a 35% relative difference in Level 2 and Level 3 hypoglycemic events, compared with a 64% treatment effect observed in Phase 2b.
Trial Conduct and Endpoint Measurement Klee addressed investor questions about trial conduct, saying the primary endpoint is a composite of Level 2 and Level 3 hypoglycemic events. Level 2 events are measured by finger-stick blood glucose readings below 54 mg per deciliter, while Level 3 events involve the need for independent rescue.
Participants complete diary entries, and Level 3 events are reviewed by an adjudication committee of expert endocrinologists using a charter that Klee said was reviewed by the U.S. Food and Drug Administration. He also noted that FDA guidance recognizes the endpoint and that avexitide has received Breakthrough Therapy designation.
Klee said Amylyx can monitor trial data nearly in real time, including finger-stick readings, diaries and blinded continuous glucose monitor data. The company uses that information to assess whether participants are consistently capturing events and following study procedures.
He also discussed dietary behavior, saying participants are trained and retrained on diet, and must certify at every visit that they are following guidance. Klee said some diet liberalization occurred in earlier Phase 2 work, but that avexitide still produced a 55% reduction in hypoglycemic events in the first Phase 2 trial.
Commercial Planning Underway Klee said Amylyx is preparing for a potential launch in 2027 if the Phase 3 study is successful. He said the company is already working on its new drug application and pre-commercial activities.
He characterized PBH as a rare disease with significant unmet need and said Amylyx is seeing growing awareness among endocrinologists. Klee said PBH is now included on endocrinology board exams and that an ICD-10 code for PBH is expected to be adopted in October.
Current care is centered on medical nutrition therapy, Klee said, including frequent small meals and avoidance of simple carbohydrates. He said physicians use a variety of off-label medications, but said they do not address the GLP-1 mechanism that Amylyx believes is central to PBH.
Klee said Amylyx is refining its go-to-market strategy and expects to focus early efforts on centers that treat large numbers of PBH patients, including academic and large endocrinology centers. He said the company is thinking about its commercial infrastructure in a rare disease framework, including field teams and digital tools.
On pricing, Klee said there are no direct analogs for PBH, but cited recent rare endocrine drug launches as potential reference points. He said Amylyx expects to work with payers to support access.
Long-Acting GLP-1 Antagonist and ALS Pipeline Klee said Amylyx is also developing AMX0318, a potential once-weekly, long-acting GLP-1 receptor antagonist. The program is in IND-enabling studies, and the company’s goal is to move it into the clinic next year. Amylyx is developing the molecule through a collaboration with Gubra, which Klee described as an expert in peptide drug development.
He said avexitide’s composition claims extend to 2037 before potential patent term extension, which could add another two to three years. Klee said further innovation, including AMX0318, could support additional intellectual property.
Klee also discussed AMX0114, Amylyx’s calpain-2 program for ALS. The intrathecally administered antisense oligonucleotide is in a multiple ascending dose study in people with ALS. Klee said the company has completed the first two dosing cohorts, is moving to cohort 3 and plans to present biomarker results from the lowest-dose cohort at an ALS conference this month.
Cash Runway Into 2028 Klee said Amylyx has cash runway into 2028. He said that guidance includes work leading up to and through a potential 2027 commercialization of avexitide, including field team buildout, inventory and launch preparations intended to support access for PBH patients.
About Amylyx Pharmaceuticals NASDAQ: AMLXAmylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Amylyx Pharmaceuticals Right Now?Before you consider Amylyx Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amylyx Pharmaceuticals wasn't on the list.
While Amylyx Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or the "Company") (NYSE: PBH). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Prestige and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 13, 2026, Prestige announced fourth quarter and full year 2026 earnings, disclosing that "for fiscal '26, revenues decreased 4.5% organically versus the prior year" and "[t]otal company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." In the associated earnings call, the Company's CEO Ron Lombardi revealed that "in Q4, Clear Eyes sales were below expectations due to delayed shipments and production shutdowns ahead of line updates."
On this news, Prestige's stock price fell $5.88 per share, or 11.35%, to close at $45.93 per share on May 14, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prestige Consumer Healthcare Inc. ("Prestige" or "the Company") (NYSE: PBH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Prestige released its Q4 and full year 2026 financial results on May 13, 2026. The Company revealed, "for fiscal 2026, revenues decreased 4.5% organically versus the prior year" and "total company adjusted gross margin of 55.6% for the year was approximately flat to 55.8% in the prior year." Based on this news, shares of Prestige fell by 11.35% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com
